The effect of treatment with risperidone, olanzapine or phenothiazines on cognitive functions in patients with schizophrenia

International Journal of Psychiatry in Clinical Practice

Volumn 5, Issue 4, 2001, Pages 249-256

  Rybakowski, J K ^a   Borkowska, A ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Neuropsychology; Olanzapine; Phenothiazines; Risperidone; Schizophrenia

Indexed keywords

OLANZAPINE; PHENOTHIAZINE DERIVATIVE; RISPERIDONE;

ADULT; AGED; ARTICLE; COGNITION; DIAGNOSTIC IMAGING; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PSYCHOMETRY; RATING SCALE; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; TASK PERFORMANCE; WORKING MEMORY;

EID: 0035675527     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500152732595     Document Type: Article

References (48)

1. Cognitive function in schizophrenia: Association with negative and positive symptoms
2. Neurocognitive correlates of positive and negative syndromes in schizophrenia
3. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia
4. Longitudinal study of cognitive function in first episode and recent-onset schizophrenia
5. Psychopathology, executive (frontal) and general cognitive impairment in relation to duration of initially untreated versus subsequently treated psychosis in chronic schizophrenia
6. Risperidone, negative symptoms and cognitive deficit in schizophrenia: An open study
7. Cognitive function in schizophrenia
8. The cognitive efficacy of atypical antipsychotics in schizophrenia
9. Neuropsychological correlates of negative, disorganized and psychotic symptoms in schizophrenia
10. Executive-frontal lobe cognitive dysfunction in schizophrenia: A symptom subtype analysis
11. Neuropsychological deficits associated with schizophrenic syndromes
12. Cognitive effects of conventional and atypical antipsychotics in schizophrenia
13. Cognitive correlates of the negative, positive, and psychotic symptom dimensions in schizophrenia
14. Effect of psychiatric disorders and their somatic treatments on neuropsychological test results
15. Continuous performance tests in schizophrenic patients: Stimulus and medication effects on performance
16. The effect of treatment with risperidone compared with phenothiazine neuroleptics on neuropsychological measurements in patients with schizophrenia
17. The effect of clozapine, risperidone and olanzapine on cognitive function in schizophrenia
18. Improvement of cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine
19. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients
20. The comparative effication and long-term effect of clozapine treatment on neuropsychological test performance
21. Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: A pilot study
22. Long-term impact of clozapine and psychosocial treatment of psychiatric symptoms and cognitive functioning
23. The effect of risperidone on cognition in patients with schizophrenia
24. Cognitive dysfunctions in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptics drugs
25. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
26. Risperidone vs haloperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients
27. Cognitive improvement in schizophrenia with novel antipsychotic medications
28. The effect of risperidone treatment on psychopathological symptoms and the results of selected neuropsychological and oculomotoric test in patients with schizophrenia
29. First episode schizophrenia: The importance of compliance and preserving cognitive function
30. Cognitive dysfunction in schizophrenia: A new set of tools for the assessment of cognition drug effects
31. Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: A prospective study
32. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol
33. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
34. The effect of clozapine therapy on frontal lobe dysfunction in schizophrenia: Neuropsychology and event-related potential measures
35. Effects of clozapine on psychiatric symptoms, cognition and functional outcome in schizophrenia
36. The effect of risperidone vs haloperidol on cognitive functioning in treatment-resistant schizophrenia: The trail making test
37. Neue bzw. atypische Neuroleptika bei schizophrener negativsymptomatik ergebnisse und methodische probleme der evaluation
38. A comparative effectiveness study of risperidone and olanzapine in treatment of schizophrenia
39. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder
40. Eye movement and neuropsychological studies in first-degree relatives of schizophrenic patients
41. The effect of olanzapine on cognitive functions in patients with schizophrenia
42. Effects of clozapine, fluphenazine, and placebo on reaction time measures of attention and sensory dominance in schizophrenia
43. Risperidone treatment of schizophrenia: Improvement in psychopathology and on neuropsychological tests
44. The relation of the trail making test to organic brain damage
45. Studies of interference in serial verbal reactions